Chronic Administration of Etoposide in the Treatment of Non-Hodgkin's Lymphoma

References

• DeVita V. T., Jr., Hubbard S. M., Longo D. L. The chemotherapy of lymphomas: looking back, moving forward-the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res. 1987; 47: 5810–5824
   PubMed Web of Science ®Google Scholar
• Shipp M. A., Yeap B. Y., Harrington D. P., et al. The m-BACOD combination chemotherapy regimen in large-cell lymphoma: analysis of the completed trial and comparison with the M-BACOD regimen. J. Clin. Oncol. 1990; 8: 84–93
   PubMed Web of Science ®Google Scholar
• Bender R. A., Anderson T., Fisher R. I., et al. Activity of the epipodophyllotoxin VP-16 in the treatment of combination chemotherapy-resistant non-Hodgkin's lymphoma. Am. J. Hematol. 1978; 5: 203–209
   PubMed Web of Science ®Google Scholar
• Mathe G., Schwarzenberg L., Pouillart P., et al. Two epipodophyllotoxin derivatives, VM26 and VP16-213, in the treatment of leukaemias, hematosarcomas, and lymphomas. Cancer 1974; 34: 985–992
   PubMed Web of Science ®Google Scholar
• Nissen N. I., Larsen V., Pedersen H., Thomsen K. Phase I clinical trial of a new antitumor agent, 4′-demethy-lepipodophyllotoxin 9 (4, 6-0-ethylidene)-B-D-glucopyran-side (NSC 141540); VP16-213. Cancer Chemother. Rep. 1972; 56: 769–777
   PubMedGoogle Scholar
• Schmoll H. Review of etoposide single-agent activity. Cancer Treat. Rev. 1982; 9(Suppl A)21–30
   PubMed Web of Science ®Google Scholar
• Cabanillas F., Hagemeister F. B., McLaughlin P., et al. Results of MIME salvage regimen for recurrent or refractory lymphoma. J. Clin. Oncol. 1987; 5: 407–412
   PubMed Web of Science ®Google Scholar
• Goss P. E., Shepherd F. A., Scott J. G., et al. Dexa-methasone/ifosfamide/cisplatin/etoposide (DICE) as therapy for patients with advanced non-Hodgkin's lymphoma: preliminary report of a phase II study. Ann. Oncol. 1991; 2: 43–46
   PubMed Web of Science ®Google Scholar
• Spitzer G., Dicke K. A., Li tarn J., et al. High-dose combination chemotherapy with autologous bone marrow transplantation in adult solid tumours. Cancer 1980; 45: 3075–3085
   PubMed Web of Science ®Google Scholar
• Gribben J. G., Goldstone A. H., Linch D. C., et al. Effectiveness of high-dose combination chemotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphomas who are still responsive to conventional-dose therapy. J. Clin. Oncol. 1989; 7: 1621–1629
   PubMed Web of Science ®Google Scholar
• Miller T. P., Dahlberg S., Weick J. K., et al. Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: A groupwide Southwest Oncology Group study. J. Clin. Oncol. 1990; 8: 1951–1958
   PubMed Web of Science ®Google Scholar
• Dombernowsky P., Nissen N. I. Schedule dependency of the antileukemic activity of the podophyllotoxin derivative VP16-213 (NSC 141540) in L1210 leukemia. Acta. Path. Microbiol. Scand. Section A. 1973; 81: 715–724
   Google Scholar
• Sullivan D. M., Glisson B. S., Hodges P. K., et al. Proliferation dependence of topoisomerase II mediated drag action. Biochem. 1986; 25: 2248–2256
   PubMed Web of Science ®Google Scholar
• Chen G. L., Yang L., Rowe T. C., et al. Nonintercalative antitumor drags interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J. Biol. Chem. 1984; 259: 13560–13566
   PubMed Web of Science ®Google Scholar
• Slevin M. L., Clark P. I., Joel S. P., et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J. Clin. Oncol. 1989; 7: 1333–1340
   PubMed Web of Science ®Google Scholar
• Hainsworth J. D., Johnson D. H., Frazier S. R., Greco F. A. Chronic daily administration of oral etoposide-A phase I trial. J. Clin. Oncol. 1989; 7: 396–401
   PubMed Web of Science ®Google Scholar
• Johnson D. H., Greco F. A., Strapp J., Hande K. R., Hainsworth J. D. Prolonged administration of oral etoposide in patients with relapsed or refractory small cell lung cancer: a phase II trial. J. Clin. Oncol. 1990; 8: 1613–1617
   PubMed Web of Science ®Google Scholar
• Hainsworth J. D., Johnson D. H., Frazier S. R., Greco F. A. Chronic daily administration of oral etoposide in refractory lymphoma. Eur. J. Cancer 1990; 26: 818–821
   PubMed Web of Science ®Google Scholar
• McMaster M. L., Greer J. P., Wolff S. N., et al. High intensity, brief duration chemotherapy for poor prognosis non-Hodgkin's lymphomas. Cancer 1991; 68: 233–241
   PubMed Web of Science ®Google Scholar
• Dixon D. O., Neilan B., Jones S. E., et al. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: The Southwest Oncology Group experience. J. Clin. Oncol. 1986; 4: 295–305
   PubMed Web of Science ®Google Scholar
• Hainsworth J. D., Johnson D. H., Greer J. P., Garrow G. C., Greco F. A. Effective, well tolerated combination chemotherapy for elderly patients with aggressive non-Hodgkin's lymphoma. Proc. Am. Soc. Clin. Oncol. 1992; 11: 336, (Abstr)
   Google Scholar
• Slevin M. L., Clark P. I., Joel S. P., et al. A randomized trial to examine the effect of more extended scheduling of etoposide administration in small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 1989; 8: 236, (Abstr)
   Google Scholar
• Hande K. R., Bennett R. B., Krozley M. G., et al. Improved bioavailability with low dose oral etoposide. Proc. Am. Soc. Clin. Oncol. 1991; 10: 96, (Abstr)
   Google Scholar
• Greco F. A., Garrow G. C., Johnson D. H., Hande K. R., Stein R. S., Hainsworth J. D. Prolonged continuous infusion of low dose etoposide in responsive neoplasms: preliminary phase I/II results. Proc. Am. Soc. Clin. Oncol. 1992; 11: 115, (Abstr)
   Google Scholar